Lipid-lowering therapy for the primary prevention of coronary heart disease

被引：24

作者：

Gotto, AM ^{[1
]}

机构：

[1] Cornell Univ, Weill Med Coll, New York, NY 10021 USA

来源：

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 1999年 / 33卷 / 07期

关键词：

D O I：

10.1016/S0735-1097(99)00114-X

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Primary prevention of coronary heart disease is a critical component of reducing the societal burden of atherosclerosis. In the current editorial, data from trials of lipid modification as primary-prevention strategies will be reviewed. Trials of the HMG-CoA reductase inhibitors have demonstrated significant benefits on coronary morbidity in patients without heart disease, and the implications of these studies on current guidelines will be discussed with a focus on the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).

引用

页码：2078 / 2082

页数：5

共 32 条

[1]

[Anonymous], 1997, Am J Cardiol, V79, P756

[2]

[Anonymous], 1994, CIRCULATION

[3] Cost-effectiveness of Pravastatin in secondary prevention of coronary artery disease [J].

Ashraf, T ;

Hay, JW ;

Pitt, B ;

Wittels, E ;

Crouse, J ;

Davidson, M ;

Furberg, CD ;

Radican, L .

AMERICAN JOURNAL OF CARDIOLOGY, 1996, 78 (04) :409-414

[4] Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels - Results of AFCAPS/TexCAPS [J].

Downs, JR ;

Clearfield, M ;

Weis, S ;

Whitney, E ;

Shapiro, DR ;

Beere, PA ;

Langendorfer, A ;

Stein, EA ;

Kruyer, W ;

Gotto, AM .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (20) :1615-1622

[5] HELSINKI HEART-STUDY - PRIMARY-PREVENTION TRIAL WITH GEMFIBROZIL IN MIDDLE-AGED MEN WITH DYSLIPIDEMIA - SAFETY OF TREATMENT, CHANGES IN RISK-FACTORS, AND INCIDENCE OF CORONARY HEART-DISEASE [J].

FRICK, MH ;

ELO, O ;

HAAPA, K ;

HEINONEN, OP ;

HEINSALMI, P ;

HELO, P ;

HUTTUNEN, JK ;

KAITANIEMI, P ;

KOSKINEN, P ;

MANNINEN, V ;

MAENPAA, H ;

MALKONEN, M ;

MANTTARI, M ;

NOROLA, S ;

PASTERNACK, A ;

PIKKARAINEN, J ;

ROMO, M ;

SJOBLOM, T ;

NIKKILA, EA .

NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (20) :1237-1245

[6] COST-EFFECTIVENESS OF HMG-COA REDUCTASE INHIBITION FOR PRIMARY AND SECONDARY PREVENTION OF CORONARY HEART-DISEASE [J].

GOLDMAN, L ;

WEINSTEIN, MC ;

GOLDMAN, PA ;

WILLIAMS, LW .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 265 (09) :1145-1151

[7] LIPID-LOWERING, REGRESSION, AND CORONARY EVENTS - A REVIEW OF THE INTERDISCIPLINARY COUNCIL ON LIPIDS AND CARDIOVASCULAR RISK INTERVENTION, 7TH COUNCIL MEETING [J].

GOTTO, AM .

CIRCULATION, 1995, 92 (03) :646-656

[8] CHOLESTEROL REDUCTION YIELDS CLINICAL BENEFIT - A NEW LOOK AT OLD DATA [J].

GOULD, AL ;

ROSSOUW, JE ;

SANTANELLO, NC ;

HEYSE, JF ;

FURBERG, CD .

CIRCULATION, 1995, 91 (08) :2274-2282

[9] Primary prevention of coronary heart disease: Guidance from Framingham - A statement for healthcare professionals from the AHA task force on risk reduction [J].

Grundy, SM ;

Balady, GJ ;

Criqui, MH ;

Fletcher, G ;

Greenland, P ;

Hiratzka, LF ;

Houston-Miller, N ;

Kris-Etherton, P ;

Krumholz, HM ;

LaRosa, J ;

Ockene, IS ;

Pearson, TA ;

Reed, J ;

Washington, R ;

Smith, SC .

CIRCULATION, 1998, 97 (18) :1876-1887

[10]

HEADY JA, 1980, LANCET, V2, P379

← 1 2 3 4 →